Mefentrifluconazole 是一种新型的唑类衍生物，广谱抗真菌 (antifungal agent) 剂。Mefentrifluconazole 是具有强效选择性和口服活性真菌 CYP51 的抑制剂 (K_d= 0.5 nM)，但是对人类芳香化酶 (IC₅₀=0.92 μM) 的抑制活性较小。

Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum antifungal agent. Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (K d = 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC 50 =0.92 μM).

Solid

CYP51A 0.5 nM (Kd)

Mefentrifluconazole undergoes extensive toxicity testing, including a full program of reproductive toxicity studies. Long term repeated dose toxicity and/or carcinogenicity studies have been conducted in rats, mice, and dogs. In each species, the highest dose level investigated gives rise to systemic toxicity.
In the acute and repeat dose toxicity studies performed with Mefentrifluconazole. A single-dose administration to rats the LD50 is >2000?mg/kg bwt by the oral route, >5000?mg/kg bwt by the dermal route, and >5.314?mg/L by inhalation as a dust aerosol. Mefentrifluconazole is not a skin or an eye irritant, nor is it a phototoxicant in vitro.
In the acute neurotoxicity study in rats, Mefentrifluconazole (oral administration; 2000?mg/kg bwt; single dose) gives rise to reduce body weight gain and transient neurobehavioral effects only

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Tesh SA, et al. Innovative selection approach for a new antifungal agent mefentrifluconazole (Revysol?) and the impact upon its toxicity profile. Regul Toxicol Pharmacol. 2019 Aug;106:152-168.

In Vitro: DMSO : 100 mg/mL (251.40 mM; Need ultrasonic)配制储备液